Detalles de la búsqueda
1.
Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S.
N Engl J Med
; 386(9): 847-860, 2022 03 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35139271
2.
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19.
N Engl J Med
; 384(23): 2187-2201, 2021 06 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-33882225
3.
Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: A double-blind randomized controlled trial.
PLoS Med
; 11(6): e1001657, 2014 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-24892763
4.
Safety and immunogenicity of Ad26.COV2.S in adults: A randomised, double-blind, placebo-controlled Phase 2a dose-finding study.
Vaccine
; 42(16): 3536-3546, 2024 Jun 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-38705804
5.
Mechanistic modeling projections of antibody persistence after homologous booster regimens of COVID-19 vaccine Ad26.COV2.S in humans.
CPT Pharmacometrics Syst Pharmacol
; 12(10): 1485-1498, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37715342
6.
Development of patient- and observer-reported outcome measures to assess COVID-19 signs and symptoms in children and adolescents.
J Patient Rep Outcomes
; 7(1): 7, 2023 01 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-36701073
7.
Quantifying Antibody Persistence After a Single Dose of COVID-19 Vaccine Ad26.COV2.S in Humans Using a Mechanistic Modeling and Simulation Approach.
Clin Pharmacol Ther
; 113(2): 380-389, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36377532
8.
Thrombosis with thrombocytopenia syndrome: A database review of clinical trial and post-marketing experience with Ad26.COV2.S.
Vaccine
; 41(37): 5351-5359, 2023 08 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-37517912
9.
Durable antibody responses elicited by 1 dose of Ad26.COV2.S and substantial increase after boosting: 2 randomized clinical trials.
Vaccine
; 40(32): 4403-4411, 2022 07 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-35667914
10.
Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Infect Dis
; 22(12): 1703-1715, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36113538
11.
Correction: Efficacy of Pneumococcal Nontypable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) in Young Latin American Children: A Double-Blind Randomized Controlled Trial.
PLoS Med
; 12(6): e1001850, 2015 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-26115379
12.
Can two different pneumococcal conjugate vaccines be used to complete the infant vaccination series? A randomized trial exploring interchangeability of the 13-valent pneumococcal conjugate vaccine and the pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine.
Expert Rev Vaccines
; 19(11): 995-1010, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-33297773
13.
Bacterial nasopharyngeal carriage following infant immunization with pneumococcal conjugate vaccines according to a 2+1 schedule in children in South Africa: an exploratory analysis of two clinical trials.
Expert Rev Vaccines
; 19(12): 1177-1189, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-33245004
14.
Impact of HIV status and vaccination schedule on bacterial nasopharyngeal carriage following infant immunisation with the pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine in South Africa.
Vaccine
; 38(10): 2350-2360, 2020 02 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-32035706
15.
Effectiveness and impact of the 10-valent pneumococcal conjugate vaccine, PHiD-CV: review of clinical trials and post-marketing experience.
Expert Rev Vaccines
; 17(9): 797-818, 2018 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-30185083
16.
Immunologic non-inferiority and safety of the investigational pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) 4-dose vial presentation compared to the licensed PHiD-CV 1-dose vial presentation in infants: A phase III randomized study.
Vaccine
; 36(5): 698-706, 2018 01 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-29277353
17.
Impact of protein D-containing pneumococcal conjugate vaccines on non-typeable Haemophilus influenzae acute otitis media and carriage.
Expert Rev Vaccines
; 16(7): 1-14, 2017 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-28571504
18.
Immunization with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) according to different schedules in infants in South Africa: a phase III trial.
Expert Rev Vaccines
; 16(6): 641-656, 2017 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-28425818
19.
Vaccination with 10-valent pneumococcal conjugate vaccine in infants according to HIV status.
Medicine (Baltimore)
; 96(2): e5881, 2017 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-28079828
20.
Efficacy of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine against acute otitis media and nasopharyngeal carriage in Panamanian children - A randomized controlled trial.
Hum Vaccin Immunother
; 13(6): 1-16, 2017 06 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-28368738